Bayesian Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-13,783
| Closed | -$499K | – | 813 |
|
|
2025
Q1 | $499K | Buy |
13,783
+5,515
| +67% | +$200K | 0.08% | 294 |
|
|
2024
Q4 | $348K | Sell |
8,268
-5,568
| -40% | -$234K | 0.04% | 457 |
|
|
2024
Q3 | $769K | Buy |
+13,836
| New | +$769K | 0.09% | 284 |
|
|
2024
Q2 | – | Sell |
-15,302
| Closed | -$714K | – | 1029 |
|
|
2024
Q1 | $714K | Buy |
+15,302
| New | +$714K | 0.07% | 368 |
|
|
2023
Q2 | – | Sell |
-16,263
| Closed | -$652K | – | 1010 |
|
|
2023
Q1 | $652K | Buy |
+16,263
| New | +$652K | 0.08% | 324 |
|
|
2022
Q2 | – | Sell |
-9,200
| Closed | -$668K | – | 1030 |
|
|
2022
Q1 | $668K | Buy |
+9,200
| New | +$668K | 0.1% | 297 |
|
|
2019
Q2 | – | Sell |
-3,753
| Closed | -$260K | – | 657 |
|
|
2019
Q1 | $260K | Buy |
+3,753
| New | +$260K | 0.05% | 420 |
|